Volume 390, Issue 10094, Pages 555-566 (August 2017) Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial  Prof H Miles Prince, MD, Prof Youn H Kim, MD, Steven M Horwitz, MD, Prof Reinhard Dummer, MD, Julia Scarisbrick, MD, Prof Pietro Quaglino, MD, Prof Pier Luigi Zinzani, MD, Pascal Wolter, MD, Jose A Sanches, PhD, Prof Pablo L Ortiz-Romero, MD, Oleg E Akilov, MD, Larisa Geskin, MD, Judith Trotman, MD, Kerry Taylor, MBBS, Prof Stephane Dalle, MD, Prof Michael Weichenthal, MD, Prof Jan Walewski, MD, David Fisher, MD, Prof Brigitte Dréno, MD, Prof Rudolf Stadler, MD, Tatyana Feldman, MD, Prof Timothy M Kuzel, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD, Erin Zagadailov, PharmD, William L Trepicchio, PhD, Wenwen Zhang, PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Dirk Huebner, MD, Meredith Little, MPH, Prof Sean Whittaker, MD, Prof Madeleine Duvic, MD Judith Trotman, David Joske, H. Miles Prince, Kerry Taylor, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Pascal Wolter, Dominique Bron, Vladmir Claudio C. de Lima, Jose Antonio Sanches, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Stephane Dalle, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Rudolf Stadler, Michael Weichenthal, Marion Wobser, Chalid Assaf, Carmen Loquai, Pietro Quaglino, Michele Spina, Pier Luigi Zinzani, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Jan Walewski, Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales, Reinhard Dummer, Timothy Illidge, Rod Johnson, Sean Whittaker, Stephen Morris, Pam McKay, Julia Scarisbrick, Madeleine Duvic, Tatyana Feldman, Oleg Akilov, Larisa Geskin, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey Prof H Miles Prince, MD, Prof Youn H Kim, MD, Steven M Horwitz, MD, Prof Reinhard Dummer, MD, Julia Scarisbrick, MD, Prof Pietro Quaglino, MD, Prof Pier Luigi Zinzani, MD, Pascal Wolter, MD, Jose A Sanches, PhD, Prof Pablo L Ortiz-Romero, MD, Oleg E Akilov, MD, Larisa Geskin, MD, Judith Trotman, MD, Kerry Taylor, MBBS, Prof Stephane Dalle, MD, Prof Michael Weichenthal, MD, Prof Jan Walewski, MD, David Fisher, MD, Prof Brigitte Dréno, MD, Prof Rudolf Stadler, MD, Tatyana Feldman, MD, Prof Timothy M Kuzel, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD, Erin Zagadailov, PharmD, William L Trepicchio, PhD, Wenwen Zhang, PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Dirk Huebner, MD, Meredith Little, MPH, Prof Sean Whittaker, MD, Prof Madeleine Duvic, MD Judith Trotman, David Joske, H. Miles Prince, Kerry Taylor, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Pascal Wolter, Dominique Bron, Vladmir Claudio C. de Lima, Jose Antonio Sanches, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Stephane Dalle, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Rudolf Stadler, Michael Weichenthal, Marion Wobser, Chalid Assaf, Carmen Loquai, Pietro Quaglino, Michele Spina, Pier Luigi Zinzani, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Jan Walewski, Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales, Reinhard Dummer, Timothy Illidge, Rod Johnson, Sean Whittaker, Stephen Morris, Pam McKay, Julia Scarisbrick, Madeleine Duvic, Tatyana Feldman, Oleg Akilov, Larisa Geskin, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey  The Lancet  Volume 390, Issue 10094, Pages 555-566 (August 2017) DOI: 10.1016/S0140-6736(17)31266-7 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2017 390, 555-566DOI: (10.1016/S0140-6736(17)31266-7) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 2 Proportion of patients achieving an objective global response lasting at least 4 months pcALCL=primary cutaneous anaplastic large-cell lymphoma. ECOG PS=Eastern Cooperative Oncology Group performance status. The Lancet 2017 390, 555-566DOI: (10.1016/S0140-6736(17)31266-7) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 3 Maximum percent change in skin mSWAT score mSWAT=modified severity weighted assessment tool. pcALCL=primary cutaneous anaplastic large-cell lymphoma. The Lancet 2017 390, 555-566DOI: (10.1016/S0140-6736(17)31266-7) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 4 Progression-free survival Progression-free survival was assessed in the intention-to-treat population overall (A) and in subgroups (B) by independent review using European Medicines Agency censoring guidelines,23 which count all events despite missed visits or starting of new anticancer therapies before an event. Assessment using US Food and Drug Administration criteria is presented in the appendix (p 14). pcALCL=primary cutaneous anaplastic large-cell lymphoma. ECOG PS=Eastern Cooperative Oncology Group performance status. The Lancet 2017 390, 555-566DOI: (10.1016/S0140-6736(17)31266-7) Copyright © 2017 Elsevier Ltd Terms and Conditions